Pharmaceutical company Acacia Pharma raises $23.5m series B financing led by Fidelity Biosciences and Novo A/S.
Acacia Pharma, a UK-based pharmaceutical company specialising in the development of drugs for cancer supportive care, has raised £15m ($23.5m) in series B financing led by venture capital firm Fidelity Biosciences and Novo A/S, the asset management holding company within Novo Group, a Denmark-based group of healthcare companies . Existing investors, growth capital investor Gilde Healthcare and life sciences venture fund Lundbeckfond Ventures, also participated in the round.
Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of Novo…
